Biochemical changes caused by the infusion into the substantia nigra of the rat of MPTP and related compounds which antagonise dihydropteridine reductase.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridinium bromide (MPP+), 1-methyl-4-(3', 4'-dihydroxyphenyl)pyridinium bromide, 4-(3',4'-dihydroxyphenyl)pyridine, 4-phenyl-1,2,3,6-tetrahydropyridine and 4-(3',4'-dimethoxyphenyl)1,2,3,6-tetrahydropyridine were infused bilaterally into the substantia nigra of the rat (10 micrograms/24 hr for 4 days). The ability to inhibit spontaneous locomotor activity and to reduce levels of neurotransmitters and metabolites in the nigrostriatal system (striatum, substantia nigra) was compared with activity to inhibit dihydropteridine reductase (DHPR) in vitro. The compound MPP+ was most effective to reduce motor responding and to decrease levels of dopamine, DOPAC and HVA (50-56%) in the striatum in addition to reducing levels of dopamine, DOPAC, noradrenaline, serotonin and 5-HIAA (42-86%) in the substantia nigra, yet MPP+ has been shown to have very weak ability to inhibit DHPR. In contrast, 4-(3',4'-dihydroxyphenyl)pyridine and 1-methyl-4-(3',4'-dihydroxyphenyl)pyridinium bromide were in the order of 10(4) and 2 X 10(5) times, respectively, more potent than MPP+ to inhibit DHPR in vitro, but these compounds failed to modify dopamine neuronal function when assessed in vivo. Therefore, there would not appear to be any correlation between the ability to modify dopamine neuronal function, as assessed behaviourally or biochemically, and ability to inhibit DHPR in synaptosomes from the striatum of the rat in vitro.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology*
D011725:Pyridines; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine